E Fund CSI Innovative Drugs ETF(516080) rises 8.18%, with a scale increase of 187 million yuan over the past week

NewTimeSpace (newtimespace.com) News, as of 11:19 on June 29, 2026, E Fund Innovative Drug ETF (516080) rose 8.18%, with the latest price at 0.65 yuan. Over a longer time frame, as of June 26, 2026, the ETF accumulated a gain of 2.22% over the past week.

In terms of liquidity, E Fund Innovative Drug ETF recorded an intraday turnover rate of 8.77% and a trading volume of 175 million yuan. Over a longer time frame, as of June 26, the ETF's average daily trading volume over the past week reached 144 million yuan, ranking in the top 3 among comparable funds.

In terms of scale, E Fund Innovative Drug ETF saw a significant increase of 187 million yuan in scale over the past week, with the new scale increase ranking 3/7 among comparable funds. (Data source: Wind)

In terms of shares, the latest share count of E Fund Innovative Drug ETF reached 3.195 billion units, hitting a one-year high and ranking 3/7 among comparable funds. (Data source: Wind)

In terms of net capital inflow, E Fund Innovative Drug ETF saw consecutive net inflows for six days, with the highest single-day net inflow reaching 65.7693 million yuan. It attracted a total of 184 million yuan, with an average daily net inflow of 30.6623 million yuan. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. E Fund Innovative Drug ETF has seen net purchases by leveraged funds for seven consecutive days, with the highest single-day net purchase reaching 3.8351 million yuan. The latest margin financing balance stood at 49.2256 million yuan. (Data source: Wind)

As of June 26, the net value of E Fund Innovative Drug ETF rose by 24.55% over the past two years, ranking first among comparable funds. From the perspective of return capability, as of June 26, 2026, since its inception, the ETF achieved a highest single-month return of 22.96%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 33.43%, and an average return of 5.62% in up months. As of June 26, 2026, the ETF's annualized excess return over its benchmark for the past three months was 4.77%, ranking in the top 2/7 among comparable funds.

In terms of drawdown, as of June 26, 2026, E Fund Innovative Drug ETF recorded a drawdown of 0.16% relative to its benchmark since the beginning of the year.

In terms of fees, E Fund Innovative Drug ETF has a management fee rate of 0.15% and a custodian fee rate of 0.05%, the lowest fee rates among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which E Fund Innovative Drug ETF tracks, is only 43.47 times, standing at the 14.39% percentile over the past year. This means the valuation is lower than over 85.61% of the time in the past year, placing it at a historical low.

E Fund Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.